Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
News for Vicarious Surgical Inc. (RBOT) centers on its progress in developing the Vicarious Surgical Robotic System and on key corporate and financing events. The company describes itself as a next-generation surgical robotics and medical device developer focused on minimally invasive surgery, with a system designed for abdominal access and 3D visualization through a single port.
Recent press releases highlight development milestones such as an in-vivo porcine lab in which surgeons used the company’s pre-DV system to complete key elements of a ventral hernia repair and evaluate subsystems including instrument articulation, energy delivery instruments and visualization. These updates provide insight into how the system performs in realistic surgical environments and how data from such labs inform design refinement, verification planning and system optimization.
Investors and observers will also find news about Vicarious Surgical’s operating model and cost structure. The company has issued cash burn guidance, discussed an operational reset, and announced reductions in headcount and external consulting spend, alongside increased use of strategic outsourcing and a strategic software execution partnership with a global digital engineering firm. These items describe how Vicarious Surgical is seeking to improve execution, increase development predictability and manage operating expenses while advancing toward system design milestones.
Additional news coverage includes quarterly financial results, registered direct offerings and private placements, at-the-market offering arrangements, board and committee changes, and participation in healthcare investment conferences. Together, these updates give a view into both the technical evolution of the Vicarious Surgical System and the company’s financing, governance and investor relations activities. Readers interested in RBOT can use this page to follow ongoing disclosures about development progress, financial guidance, capital raises and corporate governance developments.
Vicarious Surgical (OTCID: RBOT) announced strategic actions to strengthen finances and pursue a Nasdaq relisting. The company expects 2026 cash burn of approximately $19 million (down from ~$35M guidance and ~$50M mid-2025), believes cash runway extends through Q2 2026, and targets system design freeze by year-end 2026. It filed a Nasdaq listing application, a preliminary proxy to authorize a reverse stock split, and an OTCQB upgrade application while exploring capital raises.
Vicarious Surgical (OTCID: RBOT) reported Q4 and full-year 2025 results, showing reduced operating expenses and narrower losses. Total operating expenses were $9.3M in Q4 2025 and $50.0M for full year 2025, down 38% and 25% respectively versus prior periods. Cash and investments were $9.8M at year-end, full-year 2025 cash burn was $45.1M, below prior guidance, and the company expects approximately $19M cash burn for 2026.
Vicarious Surgical (NYSE: RBOT) received a delisting notice from the NYSE on March 3, 2026 after trading was suspended following market close.
The NYSE determined the company fell below the continued listing standard requiring a $15,000,000 average global market capitalization over 30 trading days. The company has ten business days to appeal and expects quotation on OTCID under symbol RBOT beginning March 4, 2026.
Vicarious Surgical (NYSE: RBOT) completed a successful in-vivo porcine lab in December 2025, advancing development of its robotic system and supporting progress toward a targeted system design freeze by end of 2026. Surgeons independently completed key elements of an intraperitoneal onlay mesh (IPOM) ventral hernia repair using the pre-DV system. The lab included three protocols: IPOM feasibility, monopolar scissors energy/cautery evaluation, and visualization and imaging assessments.
Data and structured surgeon feedback from the realistic in-vivo setting are being used for design refinement, verification planning, and system optimization. The lab was for research and development purposes only and was not designed to support regulatory submissions or clinical claims.
Vicarious Surgical (NYSE: RBOT) announced a strategic software execution partnership on December 29, 2025 to streamline operations and accelerate product development. The company has entered into an agreement with a global digital engineering and software development services firm to assume responsibility for a significant portion of software development supporting the Vicarious robotic system, including control systems, visualization, and key workflow components.
The partnership is presented as a core element of an operating model transformation intended to increase development velocity, improve milestone predictability, and reduce operating expenses and cash burn through a hybrid mix of internal and external engineering resources. Onboarding has begun via a structured transition plan to maintain continuity across active workstreams.
Vicarious Surgical (NYSE: RBOT) provided full‑year 2026 cash burn guidance of approximately $35 million, a $10 million improvement versus its updated 2025 guidance of $45 million. The company said cash needs beyond existing resources to achieve design freeze on the Vicarious Surgical system are approximately $25 million. Management attributed the improved guidance to an operational reset, including reductions in headcount and external consulting spend, partially offset by increased use of strategic outsourcing to meet critical development milestones. The company reiterated its target of achieving design freeze by year‑end 2026.
Vicarious Surgical (NYSE: RBOT) updated full-year 2025 financial guidance, now expecting cash burn of approximately $45 million, an improvement of $5 million from prior guidance of $50 million driven by disciplined cost management and an operational reset.
The company said it will provide full-year 2026 cash burn guidance before year-end to give investors visibility into the next phase. The Board also made committee appointments: Victoria Carr-Brendel as Compensation Committee chair, Fuad Ahmad to the Compensation Committee, and Joseph Doherty to the Audit Committee.
Vicarious Surgical (NYSE: WS) will participate in the Piper Sandler 37th Annual Healthcare Conference. Management is scheduled for a fireside discussion on Wednesday, December 3, 2025 at 4:30 PM ET. Interested parties can listen to a live audio webcast via the company’s investor site under Events & Presentations at the provided investor URL.
This announcement confirms the company’s investor outreach and provides the date, time, and webcast access for attendees and investors.
Vicarious Surgical (NYSE: RBOT, RBOT WS) reported third quarter 2025 results on November 12, 2025. The company reported total operating expenses of $11.5 million in Q3 2025, down 35% year-over-year, and a GAAP net loss of $11.1 million ($1.86 per share), improved from $17.1 million a year earlier. Management said it has begun implementation of a plan to reduce burn and reached design freeze progress.
The company raised $5.9 million in gross proceeds from a registered direct offering in October, held $13.4 million of cash and investments as of September 30, 2025, and recorded a Q3 cash burn of $10.5 million. Vicarious Surgical expects full-year 2025 cash burn of approximately $50 million. Management hosted a conference call on November 12, 2025.
Vicarious Surgical (NYSE: WS) will report financial results for the third quarter ended September 30, 2025 after market close on Wednesday, November 12, 2025.
Management will host a conference call beginning at 4:30 p.m. Eastern Time. Domestic callers may dial +1 833-470-1428, international callers +1 404-975-4839, using access code 623856. A live and archived webcast will be available at https://investor.vicarioussurgical.com.